Cite
HARVARD Citation
Hurvitz, S. et al. (2018). Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet oncology. 19 (1), pp. 115-126. [Online].